Still, the absence of a link with PSA levels and pathological Gleason scores raised the possibility that UGT2B17 may also have uncharacterised roles in cancer progression beyond androgen signalling.45 This possibility is supported by the observation that increased UGT2B17 expression was also associated with more aggressive chronic lymphocytic leukaemia.46,47 Further studies are thus required to evaluate whether the impact of UGT2B17 on disease progression extends beyond the AR axis in PCa.44 This evidence concerns the gene UGT2B17 and cancer.